TNFRSF10B antibody (Extracellular Domain) (PE)
Quick Overview for TNFRSF10B antibody (Extracellular Domain) (PE) (ABIN192359)
Target
See all TNFRSF10B AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- Extracellular Domain
-
Purpose
- Anti-Hu CD262 PE
-
Cross-Reactivity (Details)
- Human
-
Characteristics
- The mouse monoclonal antibody DR5-01-1 recognizes an extracellular domain of TRAIL-R2 (DR5). TRAIL-R2 is one of two TNF superfamily members that contain death domain for TRAIL (APO2L).
-
Purification
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
-
Immunogen
- Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Flow cytometry: Recommended dilution: 1-5 μg/mL, positive control: JURKAT human peripheral blood leukemia T cell line.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.1 mg/mL
-
Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Do not freeze,Protect from prolonged exposure to light
-
Storage
- 4 °C
-
Storage Comment
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
-
: "Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway." in: Carcinogenesis, Vol. 32, Issue 1, pp. 42-51, (2010) (PubMed).
-
-
- TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B))
-
Alternative Name
- CD262
-
Background
- TNF receptor superfamily member 10b,TRAIL-R2 (CD262, DR5) is one of two TNF superfamily member intracellular death domain containing receptors for TRAIL (APO2L). Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including tumor necrosis factor (TNF) and Fas ligand in the TNF family through their death domain containing receptors, TNF receptor 1 (TNFR1) and Fas, respectively. Another member in the TNF family has been identified and designated TRAIL (for TNF related apoptosis inducing ligand) and Apo2L (for Apo2 ligand). Receptors for TRAIL include two death domain containing receptors, DR4 and DR5, as well as two decoy receptors, DcR1 and DcR2, lacking the intracellular signaling death domain. DcR1 (also called TRID), like the related death receptors DR4 and DR5, contains two extracellular cysteine rich domains. However, DcR1 contains no intracellular death domain and is thus incapable of signaling apoptosis. It has been suggested DcR1 is responsible for TRAIL resistance in normal human tissues including heart, placenta, lung, liver, kidney, spleen, and bone marrow. DR5 is a member of the TNF receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor related apoptosis inducing ligand (TNFSF10/TRAIL/APO2L), and transduces apoptosis signal. Studies with FADD deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.,TNFRSF10B, KILLER, TRICK2, TRAIL-R2
-
Gene ID
- 8795
-
UniProt
- O14763
-
Pathways
- p53 Signaling, Apoptosis, Positive Regulation of Endopeptidase Activity
Target
-